Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2017)
23 slides from Vita Life Sciences's shareholder meeting presentation, May 18, 2017
Slide 1: Vita Life Sciences Annual General Meeting 2017
Welcome 2017 Vita Life Sciences Limited Annual General Meeting Vi 18 May 2017
Slide 2: Chairman's Welcome Address
1 Chairman 1. Chairman’s s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer 1
Slide 3: Managing Director's Review
Managing Directors Review
Slide 4: Appointment of Andrew O'Keefe as Group MD
¾ Appointment of Andrew O’Keefe as Group MD – January 2017 ¾ Appointment of CEO for South East Asia – Q2 ¾ Comprehensive strategic review of operations and brand position for core markets ¾ Optimise new facility in Malaysia in line with the Asian growth strategies ¾ Penetrate the China market throug
Slide 5: Asia Pacific & Australian based pharmaceutical and healthcare
¾ Asia Pacific & Australian based pharmaceutical and healthcare over-the-counter th t b i business i involved l d in i the th formulating, f l ti packaging, k i sales and distribution of vitamins and supplements ¾ 4 major brandnames ¾ Over 800 registered sku of vitamins and supplements sold in 7 cou
Slide 6: Market Population Established Revenue
2016 Population Established Market Revenue ( ) (m) since i (A$m) Australia 24 1989 15.6 Malaysia 30 2000 14.2 Si Singapore 6 1947* 59 5.9 Thailand 68 2007 China 1,371 2008 2.2 Vietnam 92 2010 Indonesia 258 2015 * As a retail pharmacy. 5
Slide 7: Revenue, EBIT and EBIT Margin
Revenue EBIT EBIT Margin-% (A$m) (A$m) (%) 40 16 8 6 30 4 12 2015 2016 2015 2016 2015 2016 ¾ Sales $37.9m (2015: $38.6m) ¾ EBIT $5.7m (2015: $6.1m) or 15.0% (2015: 15.8%) of sales ¾ Basic EPS 6.1cents (2015: 7.9cents) 6
Slide 8: Highlights and Challenges
Highlights ¾ Total dividends paid $2.0m (2015:$1.9m) ¾ Net cash of $6.9m (after borrowings) ¾ Strong cash conversion of over 90% ¾ Net cashflows generated from operations of $4.7m in FY 2016 ¾ Working capital remains strong at $14.9m to fund growth and expansion ¾ Borrowing remains low at $2.5m (201
Slide 9: Australia Overview Highlights
Overview Highlights Established: 1989 ¾ Sales $15.6m $ (2015: 15.6m) Country CEO: Mr Andrew O'Keefe ¾ EBIT record at $3.8m (2015: $3.1m) Channels: ¾ Penetration into China slowed through ¾ Independent health food stores uncertainty around E- commerce cross ¾ Independent pharmacies boarder regulation
Slide 10: Jointown Pharmaceutical Group
• Jointown Pharmaceutical group is a leading public listed company in China’s China s pharmaceutical commercial industry • Listed on the Shanghai Stock Exchange since 2010 • Involved in 4 key areas: distribution, manufacturing, retail and e-commerce • Revenue in excess of RMB 50 billion (A$9.8b) wit
Slide 11: Video Presentation of Jointown Corporate Profile
Video Presentation of Jointown Corporate Profile from Youtube https://www.youtube.com/watch?v=JDzGyXgHvYo 10
Slide 12: Video Presentation of Herbs of Gold Profile
Video Presentation of Herbs of Gold Profile from Youtube https://www.youtube.com/watch?v=whMeAmIIphA 11
Slide 13: Malaysia/Singapore Overview Highlights
Overview Highlights Established: Singapore 1947 / Malaysia 2000 ¾ Sales $20.1m $ (2015: $ $20.7m) Country CEO: Search In Progress ¾ EBIT $3.4m (2015: $3.9m) Channels: ¾ Challenging market on the back of ¾ Pharmacies slowdown in economic environment ¾ Direct to customer (MLM) ¾ Multi Level Marketing
Slide 14: Other Asia Overview Highlights
Overview Highlights Established: Various from 2008 ¾ Sales $2.2m (2015: $2.3m) Channels: ¾ EBIT Loss $1.4m (2015:$1.0m) ¾ Pharmacies ¾ Vietnam a stand out performer for this region. Brands 2016 group revenue contribution Other Asia 6% Australia Singapore 41% 16% Asia 59% Malaysia 37% 13
Slide 15: Chairman's Address
1 Chairman’s 1. Ch i ’ Address Add 2. Managing Director Director’s s Review 3. Ordinary Resolutions 4. Question & Answer 14
Slide 16: Ordinary Resolutions: Remuneration Report
1 Remuneration Report 1. 2. Re-election of Director - Mr Henry y Townsing g 3. Re-election of Director- Mr Shane Teoh 4. Share Buy-Back 5 Long Term Incentive Plan- 5. Plan Mr Andrew O’Keefe O Keefe 15
Slide 17: Resolutions proxy voting results
PROXY S PROXY’S RESOLUTIONS IN FAVOUR AGAINST ABSTAIN DISCRETION TOTALS 1) Adoption of the Remuneration Report 37 429 939 37,429,939 63 133 63,133 226 157 226,157 625 37 719 854 37,719,854 2) Re-election of Director (Mr Henry Townsing) 35,261,424 2,023,938 433,867 625 37,719,854 3) Re-election of Di
Slide 18: Chairman's Address
1 Chairman’s 1. Ch i ’ Address Add 2. Managing Director Director’s s Review 3. Ordinary Resolutions 4. Question & Answer 17
Slide 19: Contact
Contact: Telephone: +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 18
Slide 20: Year ended 31 December
Year ended 31 December 2016 2015 Change $m $m % Revenue 37.86 38.58 -1.9% EBITDA 5.97 6.21 -3.9% EBIT 5.70 6.09 -6.4% Profit before tax 5.64 6.00 -6.0% Profit after tax 3.34 4.35 -23.2% EPS (Diluted – cents) 5.88 7.69 -23.5% Dividend (cents / share) 3.75 3.75 0.0% 19
Slide 21: Balance Sheet as at 31 December
Balance Sheet as at 31 December 2016 2015 $m $m Current assets 21.75 23.52 Non-current assets 10.61 8.86 Total assets 32.36 32.38 Current liabilities (6.85) (6.87) Non-current liabilities (2.34) (2.64) Total Liabilities (9.19) (9.51) Net Assets 23.17 22.87 20
Slide 22: Cash Flow
Cash Flow 2016 2014 $m $m Receipts from customers 41.58 42.34 Payments to suppliers and employees (36.19) (36.58) Gross operating cash flow 5.39 5.76 EBITDA 5.97 6.21 Gross operating cash flow / EBITDA 90.3% 92.8% Net interest paid (0.01) (0.01) Income tax paid (0.69) (0.83) Operating cash flows 4.6
Slide 23: This document has been prepared by Vita Life Sciences Limited
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis